Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420341 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2022.07.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A 29-year-old female presented to a rheumatology-dermatology clinic with a pruritic rash that began 6 months prior, after a viral illness. She had previously been diagnosed with eczema and treated with antihistamines and topical steroids without improvement. She also noted fatigue, hair loss, and severe scalp pruritus.
View Article and Find Full Text PDFA Fleshy Mystery: Prurigo Nodularis.
Cureus
July 2024
Pathology, Louisiana State University (LSU) Health Shreveport/Rapides Regional Medical Center, Alexandria, USA.
Prurigo nodularis is a chronic dermatologic condition typically presenting as firm, dome-shaped pruritic nodules of various sizes that are often symmetrically distributed on extensor surfaces of the extremities. The diagnosis is clinical and based on a history of chronic, severe pruritis in the setting of characteristic, excoriated lesions. Treatment is difficult and aimed at reducing skin irritation and pruritus.
View Article and Find Full Text PDFGammopathic dermopathy: characterization of cutaneous MGUS.
Leuk Lymphoma
July 2024
Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a clonal plasma cell disorder that is considered preneoplastic, asymptomatic, and only requiring observation. However, MGUS may result in cutaneous complications, which are poorly understood, causing treatment delays and patient suffering. We present 30 patients with cutaneous findings associated with MGUS, characterizing clinical presentations, isoforms, treatments, and outcomes.
View Article and Find Full Text PDFPrurigo nodularis: new insights into pathogenesis and novel therapeutics.
Br J Dermatol
May 2024
Department of Dermatology.
Article Synopsis
- * The condition is influenced by specific inflammatory cytokines and neuropeptides, suggesting a complex interaction between the immune system and nerve signals that exacerbates symptoms.
- * Dupilumab is the first FDA-approved treatment for PN, with additional therapies like nemolizumab and various JAK inhibitors currently being researched for their effectiveness in managing the condition.
Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports.
World J Clin Cases
April 2023
Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China.
Article Synopsis
- Lichen amyloidosis (LA) is a tough-to-treat skin disease that often causes severe itching and can occur alongside atopic dermatitis (AD), complicating treatment options.* -
- The article discusses four patients suffering from LA and AD who initially had no relief from previous treatments but saw significant improvement after receiving dupilumab injections.* -
- The study suggests that dupilumab could be an effective new treatment option for patients dealing with both LA and AD.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!